Literature DB >> 14978671

Alteration in alpha-synuclein mRNA expression in Parkinson's disease.

Ann E Kingsbury1, Susan E Daniel, Hardev Sangha, Sarah Eisen, Andrew J Lees, Oliver J F Foster.   

Abstract

The presynaptic protein alpha-synuclein is considered to play an important role in the pathophysiology of Parkinson's disease (PD). Point mutations in the alpha-synuclein gene have been demonstrated in familial PD and alpha-synuclein is a major component of Lewy bodies, the pathological hallmark of the sporadic disease. It is not clear whether abnormal accumulation of alpha-synuclein is the result of abnormal levels of expression of the gene in neurodegenerative conditions. Expression of alpha-synuclein mRNA was therefore studied in control and PD brain using semiquantitative in situ hybridization. alpha-synuclein was expressed widely and hybridization signal was seen in most cortical regions, hippocampus, cerebellum, and brain stem. There was little mRNA in the striatum and no hybridization signal was detected in glia. High levels of alpha-synuclein mRNA expression in neurons did not seem to be a marker for Lewy body formation. Abundant signal was seen both in regions in which Lewy body deposition occurs commonly in idiopathic PD (PD), such as substantia nigra and frontal and temporal cortex, as well as in less susceptible regions, e.g. visual cortex. Quantitative comparison of mRNA expression in regions of predilection for Lewy body formation showed that mRNA expression was reduced significantly in melanized substantia nigra neurons and frontal cortex neurons in Parkinson's disease. In substantia nigra neurons there seemed to be a negative correlation between cellular mRNA expression and disease duration. These findings are in broad agreement with other studies of the expression of alpha-synuclein mRNA in human brain and suggest that Lewy body formation is unlikely to be the result of overexpression of alpha-synuclein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978671     DOI: 10.1002/mds.10683

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  35 in total

1.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

2.  Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α-Synuclein in Primary Neuronal Cultures and in Vivo.

Authors:  Georgia Dermentzaki; Nikolaos Paschalidis; Panagiotis K Politis; Leonidas Stefanis
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

3.  Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models.

Authors:  Xiaomin Su; D Luke Fischer; Xin Li; Krystof Bankiewicz; Caryl E Sortwell; Howard J Federoff
Journal:  Mol Ther       Date:  2017-05-15       Impact factor: 11.454

Review 4.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

5.  CCAAT/enhancer binding protein δ is a transcriptional repressor of α-synuclein.

Authors:  Tony Valente; Guido Dentesano; Mario Ezquerra; Ruben Fernandez-Santiago; Jonatan Martinez-Martin; Edurne Gallastegui; Carla Domuro; Yaroslau Compta; Maria J Martí; Oriol Bachs; Leonardo Márquez-Kisinousky; Marco Straccia; Carme Solà; Josep Saura
Journal:  Cell Death Differ       Date:  2019-06-17       Impact factor: 15.828

Review 6.  Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.

Authors:  Isidre Ferrer; Anna Martinez; Rosa Blanco; Ester Dalfó; Margarita Carmona
Journal:  J Neural Transm (Vienna)       Date:  2010-09-23       Impact factor: 3.575

7.  Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson's disease.

Authors:  Amélie C Lanoue; Alexandra Dumitriu; Richard H Myers; Jean-Jacques Soghomonian
Journal:  Exp Neurol       Date:  2010-09-09       Impact factor: 5.330

Review 8.  Nucleic Acid-Based Therapeutics for Parkinson's Disease.

Authors:  Masayuki Nakamori; Eunsung Junn; Hideki Mochizuki; M Maral Mouradian
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

9.  Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection.

Authors:  Viviane Labrie; Patrik Brundin
Journal:  J Innate Immun       Date:  2017-09-02       Impact factor: 7.349

10.  Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues.

Authors:  Colton Linnertz; Laura Saucier; Dongliang Ge; Kenneth D Cronin; James R Burke; Jeffrey N Browndyke; Christine M Hulette; Kathleen A Welsh-Bohmer; Ornit Chiba-Falek
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.